The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
HOME > REGULATORY
REGULATORY
- DPJ’s Committee Prepares Submission of Lawmaker-Initiated Bill to Create Third-Party Organization
May 24, 2012
- CSIMC Recommends NHI Price Listing for 8 APIs/10 Products Including Xalkori, Poteligeo
May 24, 2012
- Working Group to Set Specific Targets for 5-Year Clinical Research/Trial Activation Plan
May 22, 2012
- 1st Committee to Discuss 5 Items Including Add’l Indication of Fibromyalgia for Lyrica on June 1
May 22, 2012
- Gov’t to Form 3 Strategic Councils for Science & Technology Policy, with Its 1st Meeting for Medical Care on May 25
May 22, 2012
- 2nd Committee on New Drugs to Discuss Approval for 4 Items Including Pfizer Japan’s RCC Treatment Axitinib
May 21, 2012
- MHLW, Daiichi Sankyo Call for Proper Use of Denosumab after 3 Deaths in US
May 21, 2012
- DPJ Committee Approves Proposal to Reform Preventive Vaccination System
May 18, 2012
- DPJ Subcommittee Proposes Inclusion of 3 Subsidized Vaccines in Regular Vaccination Programs
May 16, 2012
- Gov’t to Begin Operating “Drug Discovery Network” This FY with Initial Focus on Seeds for Anticancer Agents
May 14, 2012
- DPJ’s PAL Subcommittee Calls for Establishment of Third-Party Organization within MHLW
May 11, 2012
- Expert Subcommittee on Cost-Effectiveness Assessments to Begin Discussions this Month: Policy Planning Director Sakoi
May 11, 2012
- Japan’s Application for Membership in PIC/S Reported: PIC/S General Meeting
May 11, 2012
- Risk Management Plans Must Be Submitted By 1 Month Prior to Launch: MHLW Notification
May 8, 2012
- Gov’t, Industry Leaders to Meet on May 10 for Second Dialogue on 5-Year Medical Innovation Strategy
May 8, 2012
- MHLW to Ease GCP Ordinance in Line with ICH-GCP, Promote Clinical Trials
May 7, 2012
- 1st Committee on Drugs Recommends Approval for MTPC’s DPP-4 Inhibitor Teneligliptin
May 7, 2012
- Interview with PMDA Chief Executive Tatsuya Kondo (2)
May 2, 2012
- Interview with PMDA Chief Executive Tatsuya Kondo (1)
May 1, 2012
- DPJ's PAL Subcommittee to Finalize Reform Proposal in May, Some Recommendations to Be Reflected in Economy Revival Strategy
April 27, 2012
ページ
Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…